Article
Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Mar 2013
Yu Helena A, Sima Camelia S, Huang James, Solomon Stephen B, Rimner Andreas, Paik Paul, Pietanza M Catherine, Azzoli Christopher G, Rizvi Naiyer A, Krug Lee M, Miller Vincent A, Kris Mark G, Riely Gregory J
Abstract excerpt
BACKGROUND: Development of acquired resistance limits the utility of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) for the treatment of EGFR-mutant lung cancers. There are no accepted targeted therapies for use after acquired resistance develops. Metastasectomy is used...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.